News

  • March 23, 2023

    22nd Century Group (Nasdaq: XXII) Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

    Read More
  • March 23, 2023

    22nd Century Group (XXII) Secures $21 Million Debt Financing to Expand Working Capital for Growth Initiatives

    Read More
  • March 23, 2023

    22nd Century Group (Nasdaq: XXII) to Participate in March 2023 Roth Investor Conference

    Read More
  • February 23, 2023

    22nd Century Group (XXII) Accelerates Major Growing Program to Enable Implementation of New Zealand’s Reduced-Nicotine Content Tobacco Law

    Read More
  • February 23, 2023

    Nearly Three Out of Four Colorado Smokers Want to Quit and Now Have a New Option That “Helps You Smoke Less”

    Read More
  • February 23, 2023

    22nd Century Group (Nasdaq: XXII) to Announce Fourth Quarter and Full Year 2022 Results on March 9, 2023

    Read More
  • January 23, 2023

    22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK and EU Market Position

    Read More
  • January 23, 2023

    22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master File) for CBD API; New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs

    Read More
  • January 23, 2023

    22nd Century Group (XXII) Announces U.S. Distribution Partnerships with Core-Mark and Eby-Brown

    Read More
  • January 23, 2023

    FDA’s Proposed Menthol Ban Advances to Final Rule Status, Greatly Benefits 22nd Century (XXII) by Affirming the Need for VLN(R) Menthol King as a Critical Off-Ramp for Adult Menthol Smokers

    Read More
  • December 22, 2022

    22nd Century Group (XXII) Comments on the Advancement of New Zealand’s National Reduced Nicotine Content Law

    Read More
  • December 22, 2022

    22nd Century Group Provides Update on Grass Valley Facility

    Read More
1 2 3 12